National HTA Guidelines

HIQA has a statutory remit to evaluate the clinical and cost effectiveness of health technologies, and provide advice to the Minister for Health and to the Health Service Executive (HSE). It is recognised that the findings of a HTA may have implications for other key stakeholders in the Irish healthcare system, such as patient groups, the general public, clinicians, other healthcare providers, academic groups, and the manufacturing industry. HTA guideline documents provide an overview of the principles and methods used in assessing health technologies. They act as a guide for everyone who is involved in the conduct or use of HTA in Ireland, promoting the production of assessments that are timely, reliable, consistent and relevant to the needs of decision-makers and key stakeholders in Ireland.

These guidelines are intended to inform assessments conducted by, or on behalf of HIQA, the National Centre for Pharmacoeconomics (NCPE), the Department of Health and the HSE, as well as health technology developers preparing applications for reimbursement. The guidelines are intended to be applicable to all healthcare technologies, including pharmaceuticals, procedures, medical devices, broader public health interventions and service delivery models. 

A suite of national HTA guidelines have been developed based on international best practice. These guidelines are reviewed and updated, where appropriate, to ensure that they are consistent with current best practice and that the methods and procedures reflect relevant regulatory requirements.